|Awarded On||August 20, 2014|
|Title||Development of Therapeutic Antibodies Having Both Fc[gamma] and Fc[Alpha] Effector Functions and Displaying Potent Cancer Cell Killing|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||George Georgiou|
|Cancer Sites||Breast, Colorectal|
Antibody therapeutics constitute the most significant advance in clinical oncology of the last 20 years. Antibodies are proteins that are normally produced by the immune system but can also be made by cells in bioreactors. They are Y shaped molecules in which the two “ends” of the Y molecule bind to targets on the surface of cancer cells. The “stem” region of the molecule then serves to recruit white blood (immune) cells that kill the antibody-bound cancer cell. Extensive clinical data has demonstrated that the ability of antibodies to recruit white blood cells is very important for cancer therapy. Scientists have developed ways to engineer the “stem” region of the Y -shaped antibody molecul...